Ognyan Mladenov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ognyan Mladenov has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Oscar
Department of Ophthalmology, Medical Faculty , Medical University – Sofia , Bulgaria
2 shared publications - A. Levi
Department of Ophthalmology, Medical Faculty , Medical University – Sofia , Bulgaria
1 shared publication - G. Dimitrov
Department of Ophthalmology, Medical Faculty , Medical University – Sofia , Bulgaria
1 shared publication - G. Dimitrova
Department of Ophthalmology, Medical Faculty , Medical University – Sofia , Bulgaria
1 shared publication - Nevyana Veleva
Department of Ophthalmology, Eye Clinic, University Hospital Alexandrovska, Medical University of Sofia, Sofia, Bulgaria
1 shared publication - Ralitza Georgieva
Department of Paediatrics, Medical University–Sofia, Sofia, Bulgaria
1 shared publication
Latest Publications
- Open Access
- 1 June 2026
- Published by Walter de Gruyter GmbH in Acta Medica Bulgarica
- Vol. 53 (2) , 10-15
Pharmacological, Optical, and Combined Approaches to Myopia Control in Bulgarian Children: A Longitudinal Study
This study presents different treatments, including both medication and glasses, that affect the progression of myopia in children over time. A total of 250 children aged 6 to 16 were evaluated for a period of 36 months. For the purpose of the study, four groups were formed: one group of pediatric patients receiving low-dose atropine (0.01%), another group wearing defocus-modifying glasses, a third group receiving both treatments, and a control group with no treatment. Key biometric indicators, such as axial length, spherical equivalent, and best-corrected visual acuity, were measured at the start of the study and after that every six months. Non-parametric statistical methods were used to compare changes within each group over time and to identify differences between groups. The protocol achieved high data completeness and showed significant changes within the groups (p<0.001). Clear differences between groups appeared after 12 months. The results suggest that combining atropine and defocus lenses is most effective in slowing myopia progression while maintaining good vision.
- 1 June 2026
- Published by Walter de Gruyter GmbH in Acta Medica Bulgarica
- Vol. 53 (2) , 10-15
Open AccessPharmacological, Optical, and Combined Approaches to Myopia Control in Bulgarian Children: A Longitudinal Study
This study presents different treatments, including both medication and glasses, that affect the progression of myopia in children over time. A total of 250 children aged 6 to 16 were evaluated for a period of 36 months. For the purpose of the study, four groups were formed: one group of pediatric patients receiving low-dose atropine (0.01%), another group wearing defocus-modifying glasses, a third group receiving both treatments, and a control group with no treatment. Key biometric indicators, such as axial length, spherical equivalent, and best-corrected visual acuity, were measured at the start of the study and after that every six months. Non-parametric statistical methods were used to compare changes within each group over time and to identify differences between groups. The protocol achieved high data completeness and showed significant changes within the groups (p<0.001). Clear differences between groups appeared after 12 months. The results suggest that combining atropine and defocus lenses is most effective in slowing myopia progression while maintaining good vision.
- Open Access
- 29 May 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73
Screening outcomes and treatment patterns of retinopathy of prematurity in Bulgaria: Emerging role of anti-VEGF therapy
A retrospective analysis of premature infants screened for retinopathy of prematurity (ROP) in Sofia between 2019 and 2023 included 660 infants. ROP was diagnosed in 145 infants (21.97%). Treatment was required in 97 infants (14.7% of all screened). Laser photocoagulation was performed in 80 infants (82.5% of treated cases), whereas intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy with aflibercept was administered in 17 infants (17.5%), mainly in posterior or aggressive disease. Spontaneous regression occurred in 48 infants (33.1%). No cases of endophthalmitis or systemic adverse events were observed after anti-VEGF therapy. Lower gestational age and birth weight were strongly associated with disease occurrence. These findings indicate that ROP remains a significant clinical challenge in premature infants, whereas pharmacological VEGF inhibition represents an important therapeutic option in selected severe cases, complementing conventional laser treatment.
- 29 May 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73
Open AccessScreening outcomes and treatment patterns of retinopathy of prematurity in Bulgaria: Emerging role of anti-VEGF therapy
A retrospective analysis of premature infants screened for retinopathy of prematurity (ROP) in Sofia between 2019 and 2023 included 660 infants. ROP was diagnosed in 145 infants (21.97%). Treatment was required in 97 infants (14.7% of all screened). Laser photocoagulation was performed in 80 infants (82.5% of treated cases), whereas intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy with aflibercept was administered in 17 infants (17.5%), mainly in posterior or aggressive disease. Spontaneous regression occurred in 48 infants (33.1%). No cases of endophthalmitis or systemic adverse events were observed after anti-VEGF therapy. Lower gestational age and birth weight were strongly associated with disease occurrence. These findings indicate that ROP remains a significant clinical challenge in premature infants, whereas pharmacological VEGF inhibition represents an important therapeutic option in selected severe cases, complementing conventional laser treatment.